Advanced Proteome Therapeutics Stock Net Asset

APTCF Stock  USD 0.0002  0.00  0.00%   
Advanced Proteome Therapeutics fundamentals help investors to digest information that contributes to Advanced Proteome's financial success or failures. It also enables traders to predict the movement of Advanced Pink Sheet. The fundamental analysis module provides a way to measure Advanced Proteome's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Advanced Proteome pink sheet.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Advanced Proteome Therapeutics Company Net Asset Analysis

Advanced Proteome's Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.

Net Asset

 = 

Current Market Value

-

Current Liabilities

More About Net Asset | All Equity Analysis

Current Advanced Proteome Net Asset

    
  636.41 K  
Most of Advanced Proteome's fundamental indicators, such as Net Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Advanced Proteome Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
Competition

Based on the recorded statements, Advanced Proteome Therapeutics has a Net Asset of 636.41 K. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The net asset for all United States stocks is notably lower than that of the firm.

Advanced Net Asset Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Advanced Proteome's direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Advanced Proteome could also be used in its relative valuation, which is a method of valuing Advanced Proteome by comparing valuation metrics of similar companies.
Advanced Proteome is currently under evaluation in net asset category among its peers.

Advanced Fundamentals

About Advanced Proteome Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Advanced Proteome Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Advanced Proteome using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Advanced Proteome Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Currently Active Assets on Macroaxis

Other Information on Investing in Advanced Pink Sheet

Advanced Proteome financial ratios help investors to determine whether Advanced Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Advanced with respect to the benefits of owning Advanced Proteome security.